Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
J Immunol. 2014 Aug 15;193(4):1519-24. doi: 10.4049/jimmunol.1490027.

Translational medicine in action: anti-CD20 therapy in lymphoma.

Author information

  • 1Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305.
  • 2Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305 levy@stanford.edu.


The introduction of rituximab for B cell lymphoma in the late 1990s inaugurated a new era of cancer therapy showcasing mAbs. mAbs are in principle an amalgamation of two characteristics of a perfect anticancer drug. First, rituximab is a therapy targeted to the tumor cell, but it carries fewer side effects than does chemotherapy. Second, with its ability to directly engage the host immune system, it could potentially elicit longer lasting anticancer immunity, although this remains to be proven. This review highlights the fundamental scientific discoveries that allowed the development of clinically successful anti-CD20 mAbs. Since the approval of rituximab, a considerable amount of work has been undertaken by different groups trying to understand the workings and limitations of anti-CD20s. All of these efforts will be critical in designing new mAbs to CD20 and other targets and, ultimately, of anticancer mAbs that will improve on, or even replace, chemotherapy.

Copyright © 2014 by The American Association of Immunologists, Inc.

[PubMed - in process]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk